An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.

Stock Quote

Current value on NASDAQ*

*Stock Price may not reflect real time results

SEC Filings

U.S. Securities and Exchange Commission filings
View SEC Filings

Investor Contact

Will  O’Conner
Stern Investor Relations

Indaptus Management

View Management Team

Indaptus Board of Directors

View Board of Directors

Corporate Governance

View Documents and Charters

Events and Presentations

March 14 – 15, 2022

34th Annual ROTH Conference | Webcast Link

January 10, 2022 at 7AM ET

H.C. Wainwright BioConnect 2022 Virtual Conference | Webcast Link


November 15, 2021

Investor Presentation